Literature DB >> 29051975

Impact of lesion complexity on long-term vascular response to cobalt-chromium everolimus-eluting stent: five-year follow-up optical coherence tomography study.

Shoichi Kuramitsu1, Shinjo Sonoda2, Tomohiro Shinozaki3, Hiroyuki Jinnouch4, Yoshitaka Muraoka2, Takenori Domei4, Makoto Hyodo4, Shinichi Shirai4, Kenji Ando4, Yutaka Otsuji2.   

Abstract

The impact of lesion complexity on long-term vascular response to cobalt-chromium everolimus-eluting stent (CoCrEES) remains unclear. We sought to evaluate them using optical coherence tomography (OCT). A total of 47 patients with 58 lesions treated only with CoCrEES and no target-vessel events within 5 years after implantation were prospectively enrolled and underwent 5-year follow-up OCT. Quantitative parameters and qualitative characteristics of the neointima were evaluated using multilevel logistic or linear regression models with random effects at three levels: lesion, cross-section (CS), and strut. According to the lesion complexity, the lesions were classified into the two groups: the complex lesion (CL) and non-CL group. The CL was defined as having at least 1 high-risk feature such as acute coronary syndrome lesion, lesion length > 20 mm, severe calcification requiring rotational atherectomy, and chronic total occlusion at the index procedure. A total of 11,034 struts (CL, n = 6240; non-CL, n = 4794) and 1202 (CL, n = 683; non-CL, n = 519) CSs were analyzed. The percentage of uncovered and malapposed struts did not differ significantly between the CL and non-CL groups (0.90 vs. 0.54%, P = 0.78; 0.56 vs. 0.10%, P = 0.16, respectively). The incidence of neoatherosclerosis was comparable between both groups in the CS- and lesion-level analysis (3.5 vs. 4.6%, P = 0.91; 32.0 vs. 24.2%, P = 0.52, respectively). At 5 years, CoCrEES shows an excellent vascular healing and similar frequency of neoatheroslerosis in patients without target-vessel events, regardless of the lesion complexity.

Entities:  

Keywords:  Cobalt–chromium everolimus-eluting stent; Lesion complexity; Long-term vascular response; Optical coherence tomography

Mesh:

Substances:

Year:  2017        PMID: 29051975     DOI: 10.1007/s00380-017-1068-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  23 in total

1.  Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition.

Authors:  Jun Tanigawa; Peter Barlis; Carlo Di Mario
Journal:  EuroIntervention       Date:  2007-05       Impact factor: 6.534

2.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

3.  Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation.

Authors:  Soo-Jin Kang; Gary S Mintz; Takashi Akasaka; Duk-Woo Park; Jong-Young Lee; Won-Jang Kim; Seung-Whan Lee; Young-Hak Kim; Cheol Whan Lee; Seong-Wook Park; Seung-Jung Park
Journal:  Circulation       Date:  2011-06-06       Impact factor: 29.690

4.  The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry.

Authors:  Masaru Kuroda; Hiromasa Otake; Toshiro Shinke; Tomofumi Takaya; Masayuki Nakagawa; Tsuyoshi Osue; Yu Taniguchi; Masamichi Iwasaki; Ryo Nishio; Hiroto Kinutani; Akihide Konishi; Ken-Ichi Hirata
Journal:  EuroIntervention       Date:  2016-12-10       Impact factor: 6.534

5.  5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Authors:  Hemal Gada; Ajay J Kirtane; William Newman; Mark Sanz; James B Hermiller; Kenneth W Mahaffey; Donald E Cutlip; Krishnankutty Sudhir; Liming Hou; Kai Koo; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2013-11-13       Impact factor: 11.195

6.  Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial.

Authors:  Lisette Okkels Jensen; Per Thayssen; Michael Maeng; Evald Høj Christiansen; Jan Ravkilde; Knud Nørregaard Hansen; Anne Kaltoft; Hans Henrik Tilsted; Morten Madsen; Jens Flensted Lassen
Journal:  JACC Cardiovasc Interv       Date:  2014-07-30       Impact factor: 11.195

7.  Impact of strut-vessel distance and underlying plaque type on the resolution of acute strut malapposition: serial optimal coherence tomography analysis after everolimus-eluting stent implantation.

Authors:  Takumi Inoue; Toshiro Shinke; Hiromasa Otake; Masayuki Nakagawa; Hirotoshi Hariki; Tsuyoshi Osue; Masamichi Iwasaki; Yu Taniguchi; Ryo Nishio; Noritoshi Hiranuma; Akihide Konishi; Hiroto Kinutani; Masaru Kuroda; Ken-ichi Hirata
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-19       Impact factor: 2.357

8.  Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.

Authors:  Manel Sabaté; Salvatore Brugaletta; Angel Cequier; Andrés Iñiguez; Antonio Serra; Pilar Jiménez-Quevedo; Vicente Mainar; Gianluca Campo; Maurizio Tespili; Peter den Heijer; Armando Bethencourt; Nicolás Vazquez; Gerrit Anne van Es; Bianca Backx; Marco Valgimigli; Patrick W Serruys
Journal:  Lancet       Date:  2015-10-29       Impact factor: 79.321

9.  Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.

Authors:  Shoichi Kuramitsu; Yoshio Kazuno; Shinjo Sonoda; Takenori Domei; Hiroyuki Jinnouchi; Kyohei Yamaji; Yoshimitsu Soga; Shinichi Shirai; Kenji Ando; Shigeru Saito
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-09-01       Impact factor: 6.875

10.  First-Generation Versus Second-Generation Drug-Eluting Stents in Coronary Chronic Total Occlusions: Two-Year Results of a Multicenter Registry.

Authors:  Jong-Hwa Ahn; Jeong Hoon Yang; Cheol Woong Yu; Je Sang Kim; Hyun Jong Lee; Rak Kyeong Choi; Tae Hoon Kim; Ho Joon Jang; Young Jin Choi; Young Moo Roh; Won-Heum Shim; Young Bin Song; Joo-Yong Hahn; Jin-Ho Choi; Sang Hoon Lee; Hyeon-Cheol Gwon; Seung-Hyuk Choi
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

View more
  1 in total

Review 1.  Drug-eluting stent thrombosis: current and future perspectives.

Authors:  Shoichi Kuramitsu; Shinjo Sonoda; Kenji Ando; Hiromasa Otake; Masahiro Natsuaki; Reo Anai; Yasuhiro Honda; Kazushige Kadota; Yoshio Kobayashi; Takeshi Kimura
Journal:  Cardiovasc Interv Ther       Date:  2021-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.